Cytokinetics Inc vs Okta, Inc. — how do they compare? Cytokinetics Inc trades at $76.27 (market cap $10.63B), while Okta, Inc. trades at $151.95 (market cap $26.13B). The key difference: Okta, Inc. is far larger — about 2.5× Cytokinetics Inc's market cap, and Okta, Inc. is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals.
| CYTK | OKTA | |
|---|---|---|
Market Cap | $10.63B | $26.13B |
Sector | Technology | Technology |
52-Week High | $87.26 | $154.62 |
52-Week Low | $34.31 | $62.93 |
Enterprise Value | $10.74B | $23.95B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
OKTA trades at $150.77, up 1.65% today, with a bullish technical signal from moving averages and strong quarterly earnings beats. Revenue grew to $2.61B in 2025, achieving a net income of $28M after recent losses. The company maintains a 77.44% gross margin and positive operating cash flow of $750M, supported by strategic acquisitions like Permiso Security for AI threat defense.
Outlook remains positive with 72.55% analyst buy ratings and a consensus price target of $129.71, though high valuation ratios (P/E 108.93) and overbought RSI levels near 76.86 pose risks. Key catalysts include Q2 2026 earnings on August 26, 2026, and growth in cybersecurity demand.
Trailing returns across standard periods
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →